Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616392 | 0.89 | ACHE (0.47) | ACHEBCHE | |
| SCHEMBL17288405 | 0.77 | DRD2 (0.32) | ACHE | |
| SCHEMBL17288964 | 0.75 | ALOX12 (0.39) | ACHE | |
| SCHEMBL8729417 | 0.74 | ACHE (0.45) | ACHEBCHE | |
| SCHEMBL1616193 | 0.73 | ADRA1A (0.43) | ACHE | |
| SCHEMBL15049790 | 0.72 | HSD11B1 (0.41) | ACHE | |
| SCHEMBL22568912 | 0.71 | ACHE (0.47) | ACHEBCHE | |
| 1,2-Dimethoxybenzene SCHEMBL28942667 | 0.71 | CA1 (0.62) | — | |
| SCHEMBL506893 | 0.71 | DRD2 (0.54) | — | |
| SCHEMBL17288465 | 0.71 | BCL2L1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2262773-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109491-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | HTR5A, HTR2C, HTR2B | ACHE 436/4885BCHE 1765/4885 |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | ACHE 1087/4885BCHE 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.